BH.IMMUN&BIO | SYNCOM FORMULATIONS | BH.IMMUN&BIO/ SYNCOM FORMULATIONS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.3 | 46.5 | - | View Chart |
P/BV | x | 1.4 | 4.8 | 30.0% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BH.IMMUN&BIO SYNCOM FORMULATIONS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
SYNCOM FORMULATIONS Mar-23 |
BH.IMMUN&BIO/ SYNCOM FORMULATIONS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 13 | 398.5% | |
Low | Rs | 21 | 5 | 450.5% | |
Sales per share (Unadj.) | Rs | 10.3 | 2.4 | 433.0% | |
Earnings per share (Unadj.) | Rs | -3.9 | 0.2 | -1,804.7% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 0.3 | -1,454.1% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | 2.7 | 750.1% | |
Shares outstanding (eoy) | m | 43.18 | 940.00 | 4.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 3.7 | 95.1% | |
Avg P/E ratio | x | -9.4 | 41.1 | -22.8% | |
P/CF ratio (eoy) | x | -9.5 | 33.5 | -28.3% | |
Price / Book Value ratio | x | 1.8 | 3.2 | 54.9% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 8,249 | 18.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 244 | 62.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 2,243 | 19.9% | |
Other income | Rs m | 11 | 146 | 7.3% | |
Total revenues | Rs m | 457 | 2,389 | 19.1% | |
Gross profit | Rs m | -161 | 199 | -80.7% | |
Depreciation | Rs m | 2 | 45 | 4.4% | |
Interest | Rs m | 71 | 34 | 207.6% | |
Profit before tax | Rs m | -223 | 266 | -83.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 65 | -86.6% | |
Profit after tax | Rs m | -166 | 201 | -82.9% | |
Gross profit margin | % | -36.0 | 8.9 | -405.7% | |
Effective tax rate | % | 25.3 | 24.5 | 103.3% | |
Net profit margin | % | -37.3 | 8.9 | -416.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 1,817 | 19.7% | |
Current liabilities | Rs m | 940 | 1,132 | 83.1% | |
Net working cap to sales | % | -130.6 | 30.6 | -427.2% | |
Current ratio | x | 0.4 | 1.6 | 23.7% | |
Inventory Days | Days | 85 | 231 | 36.9% | |
Debtors Days | Days | 1,135 | 1,229 | 92.4% | |
Net fixed assets | Rs m | 1,262 | 1,961 | 64.3% | |
Share capital | Rs m | 432 | 940 | 45.9% | |
"Free" reserves | Rs m | 450 | 1,620 | 27.8% | |
Net worth | Rs m | 882 | 2,560 | 34.5% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,620 | 3,778 | 42.9% | |
Interest coverage | x | -2.2 | 8.8 | -24.4% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0.6 | 46.4% | |
Return on assets | % | -5.9 | 6.2 | -95.2% | |
Return on equity | % | -18.9 | 7.8 | -240.6% | |
Return on capital | % | -17.2 | 11.7 | -147.3% | |
Exports to sales | % | 0 | 63.3 | 0.0% | |
Imports to sales | % | 14.5 | 7.7 | 188.3% | |
Exports (fob) | Rs m | NA | 1,419 | 0.0% | |
Imports (cif) | Rs m | 65 | 172 | 37.5% | |
Fx inflow | Rs m | 0 | 1,419 | 0.0% | |
Fx outflow | Rs m | 65 | 204 | 31.6% | |
Net fx | Rs m | -65 | 1,215 | -5.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 105 | 103.4% | |
From Investments | Rs m | 5 | -450 | -1.0% | |
From Financial Activity | Rs m | -147 | 350 | -42.0% | |
Net Cashflow | Rs m | -34 | 6 | -580.8% |
Indian Promoters | % | 59.3 | 50.6 | 117.2% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.1 | - | |
FIIs | % | 0.0 | 0.1 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 49.4 | 82.4% | |
Shareholders | 35,313 | 325,761 | 10.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | SYNCOM FORMULATIONS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.51% | 0.54% | 0.88% |
1-Month | -6.65% | -1.51% | -2.81% |
1-Year | 27.90% | 113.93% | 48.83% |
3-Year CAGR | -17.31% | 30.15% | 12.15% |
5-Year CAGR | 30.24% | 67.49% | 20.25% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the SYNCOM FORMULATIONS share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of SYNCOM FORMULATIONS the stake stands at 50.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of SYNCOM FORMULATIONS.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
SYNCOM FORMULATIONS paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of SYNCOM FORMULATIONS.
For a sector overview, read our pharmaceuticals sector report.
On Friday, Indian share markets traded on a positive note throughout the trading session and ended higher.